PDS Biotechnology Sees 693.73% Upside Potential, HC Wainwright Maintains Buy Recommendation

HC Wainwright & Co. maintains a Buy recommendation for PDS Biotechnology (PDSB), with an average one-year price target of $7.65/share, representing a 693.73% increase from its latest closing price of $0.96/share. The firm projects annual revenue of $7MM and non-GAAP EPS of -$1.14. Total shares owned by institutions decreased by 10.85% to 7,840K shares in the last three months. Armistice Capital holds 2,236K shares, representing 4.75% ownership of the company.